edotreotide has been researched along with Argentaffinoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Albano, D; Bertagna, F; Giubbini, R | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R; Venkitaraman, B | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R; Malhotra, A; Meena, M; Venkitaraman, B | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 2 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Angelini, C; Caprotti, R; Crippa, S; Mussi, C; Sartori, P; Uggeri, F | 1 |
| Bartenstein, PR; Brockmann, JJ; Buchholz, HG; Engelbach, MJ; Förster, GJ; Herzog, HR; Mäcke, HR; Reber, HJ; Rösch, FR | 1 |
| Börner, R; Henze, M; Heppeler, A; Hofmann, M; Knapp, H; Maecke, H; Meyer, J; Oei, L; Schöffski, P; Schumacher, J; Weckesser, E | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C | 1 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
1 trial(s) available for edotreotide and Argentaffinoma
| Article | Year |
|---|---|
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
12 other study(ies) available for edotreotide and Argentaffinoma
| Article | Year |
|---|---|
Thyroid metastasis from lung carcinoid detected by
Topics: Carcinoid Tumor; Gallium Radioisotopes; Humans; Lung; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Gland | 2021 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
Role of 68Ga-DOTATOC PET/CT in carcinoids.
Topics: Carcinoid Tumor; Cushing Syndrome; Humans; Lung Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
Topics: Adolescent; Adult; Carcinoid Tumor; Female; Gallium Radioisotopes; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Topics: Adolescent; Adult; Carcinoid Tumor; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Middle Aged; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
90Y-DOTATOC and nephrotoxicity.
Topics: Animals; Carcinoid Tumor; Humans; Intestinal Neoplasms; Kidney; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Octreotide; Palliative Care; Radiopharmaceuticals; Yttrium | 2005 |
End-stage renal disease after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals | 2001 |
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Topics: Aged; Carcinoid Tumor; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Radiation Dosage; Radiometry; Radiopharmaceuticals; Somatostatin; Tissue Distribution; Tomography, Emission-Computed; Yttrium Radioisotopes | 2001 |
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Topics: Aged; Carcinoid Tumor; Female; Gallium Radioisotopes; Humans; Indium Radioisotopes; Liver Neoplasms; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2001 |
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Topics: Carcinoid Tumor; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pain, Intractable; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2002 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |